APTA Stock Overview
Provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aptamer Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0027 |
| 52 Week High | UK£0.014 |
| 52 Week Low | UK£0.002 |
| Beta | -0.60 |
| 11 Month Change | 34.15% |
| 3 Month Change | 19.57% |
| 1 Year Change | -77.08% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.81% |
Recent News & Updates
Shareholder Returns
| APTA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 14.6% | -1.7% | -1.0% |
| 1Y | -77.1% | -19.2% | 6.9% |
Return vs Industry: APTA underperformed the UK Biotechs industry which returned -20.6% over the past year.
Return vs Market: APTA underperformed the UK Market which returned 5.1% over the past year.
Price Volatility
| APTA volatility | |
|---|---|
| APTA Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: APTA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: APTA's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 34 | Arron Tolley | aptamergroup.com |
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, and internationally. The company offers Optimer platform that enables the discovery and development of oligonucleotide binders; custom development services for oligonucleotide-based aptamer and Optimer binders; solutions to bioprocessing, diagnostic, and pharmaceutical scientists; and contract research services in the field of therapeutics. It serves pharma companies, diagnostic development companies, and research institutes.
Aptamer Group plc Fundamentals Summary
| APTA fundamental statistics | |
|---|---|
| Market cap | UK£5.28m |
| Earnings (TTM) | -UK£2.96m |
| Revenue (TTM) | UK£860.00k |
6.1x
P/S Ratio-1.8x
P/E RatioIs APTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APTA income statement (TTM) | |
|---|---|
| Revenue | UK£860.00k |
| Cost of Revenue | UK£610.00k |
| Gross Profit | UK£250.00k |
| Other Expenses | UK£3.21m |
| Earnings | -UK£2.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0015 |
| Gross Margin | 29.07% |
| Net Profit Margin | -343.95% |
| Debt/Equity Ratio | 5.3% |
How did APTA perform over the long term?
See historical performance and comparison